Systemic lupus erythematosus (SLE) is a chronic, autoimmune rheumatic disease with many clinical presentations typically affecting women of childbearing age. The successful therapy of SLE depends upon treating both symptoms and the underlying inflammation. Both non-pharmacological as well as pharmacological therapies are invariably required. Non-pharmacological therapy includes avoiding over-exposure to sunlight with the use of adequate sunscreen protection, avoiding “live” vaccination if on immunosuppressive agents, adherence to a diet low in saturated fat and high in fish oil, stress avoidance, and smoking cessation.

Pharmacological measures revolve around four main classes of drugs: non-steroidal anti-inflammatory drugs, antimalarials, corticosteroids, and cytotoxic agents. Cyclophosphamide and azathioprine are the two most commonly used cytotoxic agents and these in combination with corticosteroids need to be employed early if there is major organ involvement to prevent or minimise irreversible damage. The potential side effects of corticosteroids and cytotoxic agents need constant consideration. The rapid developments in biotechnology of recent years may soon lead to new and more specific therapies for patients with SLE.

The term “lupus erythematous” was first coined by Cazenave and Clausit in 1852 and yet 150 years later this condition continues to challenge the physician’s capability to deliver safe and effective therapy. Systemic lupus erythematosus (SLE) is a multisystemic, chronic condition affecting individual patients in diverse ways over a varying course of time. Moreover, potential life threatening organ involvement may not cause symptoms until irreversible damage has occurred. Conversely other features such as fatigue, though not life threatening, is for many the single most debilitating feature of their disease. Thus therapy must be tailored to not only suppress disease activity but also to adequately control symptoms. Furthermore there is a need to use the most appropriate regimen of drugs, often long term, to achieve both these goals while acknowledging potential long term side effects of the agents employed. For example some agents commonly used have potential effects on fertility. Given that SLE typically affects young women of childbearing age. The successful therapy of SLE depends upon treating both symptoms and the underlying inflammation. Both non-pharmacological as well as pharmacological therapies are invariably required. Non-pharmacological therapy includes avoiding over-exposure to sunlight with the use of adequate sunscreen protection, avoiding “live” vaccination if on immunosuppressive agents, adherence to a diet low in saturated fat and high in fish oil, stress avoidance, and smoking cessation.

Pharmacological measures revolve around four main classes of drugs: non-steroidal anti-inflammatory drugs, antimalarials, corticosteroids, and cytotoxic agents. Cyclophosphamide and azathioprine are the two most commonly used cytotoxic agents and these in combination with corticosteroids need to be employed early if there is major organ involvement to prevent or minimise irreversible damage. The potential side effects of corticosteroids and cytotoxic agents need constant consideration. The rapid developments in biotechnology of recent years may soon lead to new and more specific therapies for patients with SLE.

The term “lupus erythematous” was first coined by Cazenave and Clausit in 1852 and yet 150 years later this condition continues to challenge the physician’s capability to deliver safe and effective therapy. Systemic lupus erythematosus (SLE) is a multisystemic, chronic condition affecting individual patients in diverse ways over a varying course of time. Moreover, potential life threatening organ involvement may not cause symptoms until irreversible damage has occurred. Conversely other features such as fatigue, though not life threatening, is for many the single most debilitating feature of their disease. Thus therapy must be tailored to not only suppress disease activity but also to adequately control symptoms. Furthermore there is a need to use the most appropriate regimen of drugs, often long term, to achieve both these goals while acknowledging potential long term side effects of the agents employed. For example some agents commonly used have potential effects on fertility. Given that SLE typically affects young women of childbearing age. The successful therapy of SLE depends upon treating both symptoms and the underlying inflammation. Both non-pharmacological as well as pharmacological therapies are invariably required. Non-pharmacological therapy includes avoiding over-exposure to sunlight with the use of adequate sunscreen protection, avoiding “live” vaccination if on immunosuppressive agents, adherence to a diet low in saturated fat and high in fish oil, stress avoidance, and smoking cessation.

Pharmacological measures revolve around four main classes of drugs: non-steroidal anti-inflammatory drugs, antimalarials, corticosteroids, and cytotoxic agents. Cyclophosphamide and azathioprine are the two most commonly used cytotoxic agents and these in combination with corticosteroids need to be employed early if there is major organ involvement to prevent or minimise irreversible damage. The potential side effects of corticosteroids and cytotoxic agents need constant consideration. The rapid developments in biotechnology of recent years may soon lead to new and more specific therapies for patients with SLE.

The term “lupus erythematous” was first coined by Cazenave and Clausit in 1852 and yet 150 years later this condition continues to challenge the physician’s capability to deliver safe and effective therapy. Systemic lupus erythematosus (SLE) is a multisystemic, chronic condition affecting individual patients in diverse ways over a varying course of time. Moreover, potential life threatening organ involvement may not cause symptoms until irreversible damage has occurred. Conversely other features such as fatigue, though not life threatening, is for many the single most debilitating feature of their disease. Thus therapy must be tailored to not only suppress disease activity but also to adequately control symptoms. Furthermore there is a need to use the most appropriate regimen of drugs, often long term, to achieve both these goals while acknowledging potential long term side effects of the agents employed. For example some agents commonly used have potential effects on fertility.

Given that SLE typically affects young women of childbear-
progesterone only pill, or indeed other methods of contraception encouraged. The use of hormone replacement therapy (HRT) remains controversial with some patients anecdotally linking flares to starting HRT. The effects of exogenous oestrogen in SLE is currently being studied in a multicentre, randomised, placebo controlled trial (Safety of Estrogen in SLE: National Assessment, SELINA study) which is approaching completion and should resolve this area of uncertainty.

Other general measures that maybe taken are the avoidance of stress, rest as appropriate and a low saturated fat, high fish oil containing diet. Patients with SLE have a high incidence of premature deaths from accelerated atherosclerotic disease, and thus adherence to a more general cardioprotective lifestyle such as cessation of smoking should be strongly encouraged.

**PHARMACOLOGICAL MANAGEMENT**

The pharmacological management of patients with SLE presently revolves around four main classes of drugs, often in combination. These are:

- Non-steroidal anti-inflammatory drugs (NSAIDs).
- Antimalarials.
- Corticosteroids.
- Cytotoxic drugs.

The broad indication for the use of these drugs are summarised in table 1 and figure 1 and are discussed in greater depth. Table 2 summarises some of the potential side effects and measures that may be taken to limit these. Generally however recommendations regarding when to commence therapy, initial dose and duration of treatment continue to

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Drug therapy in SLE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NSAIDs</td>
</tr>
<tr>
<td>Malaise</td>
<td>–</td>
</tr>
<tr>
<td>Fever</td>
<td>+</td>
</tr>
<tr>
<td>Serositis</td>
<td>+</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>+</td>
</tr>
<tr>
<td>Arthritis</td>
<td>+</td>
</tr>
<tr>
<td>Myalgia</td>
<td>+</td>
</tr>
<tr>
<td>Malar/discoid rash</td>
<td>–</td>
</tr>
<tr>
<td>Pneumonitis</td>
<td>–</td>
</tr>
<tr>
<td>Cardits</td>
<td>–</td>
</tr>
<tr>
<td>Vascularitis</td>
<td>–</td>
</tr>
<tr>
<td>CNS</td>
<td>–</td>
</tr>
<tr>
<td>Renal</td>
<td>–</td>
</tr>
<tr>
<td>Haemolytic anaemia</td>
<td>–</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>–</td>
</tr>
<tr>
<td>Raynauds</td>
<td>–</td>
</tr>
<tr>
<td>Alopecia</td>
<td>–</td>
</tr>
</tbody>
</table>

+, Usually beneficial; –, not beneficial; ?, dubious/controversial; *, widely prescribed though evidence regarding its efficacy is largely lacking. CNS, central nervous system.

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Major side effects of drugs commonly used in SLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug</td>
<td>Side effect</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>Gastrointestinal irritation/ bleeding</td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td>Retinopathy (rare)</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>Osteoporosis</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>Bone marrow toxicity</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>Bone marrow toxicity</td>
</tr>
<tr>
<td>Haemorrhagic cystitis</td>
<td>Good hydration (IV fluids if giving IV cyclophosphamide)</td>
</tr>
<tr>
<td>Increased risk of malignancy</td>
<td>Mean is protective: oral or IV</td>
</tr>
<tr>
<td>Infertility/amenorrhoea</td>
<td>Powerful antiemetics such as granisetron often necessary</td>
</tr>
</tbody>
</table>

COX, cyclo-oxygenase; IV, intravenous; NICE, National Institute of Clinical Excellence.
vary widely. This variation in practice has motivated an international effort via the SLICC (Systemic Lupus International Collaborative Clinics group) to validate existing disease activity measures such as the British BILAG (British Isle Lupus Assessment Group), US SLAM (Systemic Lupus Activity Measure) and Canadian SLEDAI (SLE Disease Activity Index) in addition to formulating a validated damage index. By more accurately quantifying disease activity and disease damage intervention with appropriate therapy via standardised treatment protocols can lead to a greater quality of care and a greater uniformity in practice between centres. The SLICC group is currently aiming to define a drug responder index for patients with SLE.

Non-steroidal anti-inflammatory drugs and antimalarials

Patients with mild lupus can generally be maintained on a combination of NSAIDs and antimalarials. NSAIDs significantly increase the risk of developing peptic ulceration. Given that patients with lupus often take NSAIDs regularly, long term appropriate precautions such as co-prescribing gastroprotective agents for example should be considered. Particular caution with regards to the nephrotoxic side effects of NSAIDs is advised in patients with lupus nephritis as this group of patients often have abnormal renal function.

The antimalarial drug of choice is hydroxychloroquine (Plaquenil). This is most commonly employed to treat patients whose over-riding symptoms are those of fatigue, arthralgia/ arthritis, and rash without major organ involvement. A small randomised trial has shown that patients who discontinued hydroxychloroquine were more likely to develop flares often characterised by fatigue, arthralgia, and/or rash. The starting dose is 400 mg daily, is generally tolerated well and patients should be advised that onset of action may take as long as six to eight weeks. A rare but potentially serious side effect is retinal toxicity with an approximate prevalence of 0.5%. Most centres thus refer patients to ophthalmologists for baseline screening and have subsequent assessments every 12 months, though a review has proposed that there is no conclusive evidence supporting such frequent assessments. Hydroxychloroquine has also been shown to help lower total triglyceride levels, very low density lipoprotein-cholesterol, and apolipoprotein CIII levels.

Treatment with corticosteroids

Relatively low dose corticosteroids are used when NSAIDs and antimalarials have failed to control symptoms of arthralgia/ arthritis or rash sufficiently. When there is major organ involvement with potential life threatening sequelae corticosteroids are used at higher doses (table 1 and fig 1). Examples are autoimmune haemolytic anaemia, lupus nephritis (fig 2), severe pericarditis, and neuropsychiatric involvement.

The route of administration and initial doses varies depending on the type and severity of presentation and different centres probably differ in their precise protocol. Generally corticosteroids are taken orally with the dose varying according to severity and type of organ involvement. Intramuscular methylprednisolone (Dep-Medrone) or hydrocortisone (Del-tastab) maybe useful in terminating a mild flare characterised...
by fatigue and/or arthralgia, which may be precipitated by a preceding viral infection for example. Intravenous use of pulsed methylprednisolone has been widely used for the past 20 years. Our practice is to give 750 mg to 1 g on three successive days for patients with severe disease responding poorly to oral prednisolone. The infusion is given slowly over 3–4 hours to minimise possible reactions such as arthritis, flushing, headache, or tachycardia.

Many patients with SLE need aggressive, often long term therapy with corticosteroids to preserve major organ function. Hence many are exposed to the potentially hazardous side effects of corticosteroids and are thus no panacea (table 2). The long list of side effects includes major risk of infection, hyperlipidaemia, hypertension, osteoporosis, diabetes, insomnaiia, and alopecia. All of these side effects may have significant and specific implications in a patient with active lupus as follows: infection is a leading cause of mortality in patients with lupus, patients with active SLE have a high incidence of accelerated atherosclerotic disease, it is vital that hypertension is aggressively controlled in patients with lupus nephritis, patients with premature ovarian failure secondary to cytotoxic therapy are at significant risk of severe osteoporosis. Thus the treating physician must be alert to all these potential hazards, which may be exacerbated by indiscriminate use of high dose corticosteroids.

The issue of osteoporosis needs to be addressed in some detail as cross sectional studies have identified low bone mineral density in SLE patients when compared with age matched controls. Patients with SLE are at significant risk of developing osteoporosis through several factors: the inflammatory disease itself, disease related co-morbidity, and its treatment. Hence all patients should be assessed for additional risk factors for osteoporosis and general lifestyle measures adopted: these include smoking cessation, moderate consumption of alcohol, adequate intake of dietary calcium and vitamin D, and regular weight bearing exercise. The relationship between corticosteroids and osteoporosis has been specifically examined in SLE in several studies. Risk of fracture is related to length of treatment and cumulative exposure. Hence the practice at our centre for patients taking prednisolone 7.5 mg daily or more is to start calcium and vitamin D supplements, advocate general “bone protective” lifestyle measures, and perform a bone mineral density scan every two years approximately. Several randomised controlled studies have confirmed the efficacy of bisphosphonates in treating corticosteroid induced bone loss and reducing risk of vertebral fractures. Thus patients with a bone mineral density T score of below ~2.5 should be prescribed a bisphosphonate unless contraindicated for greater bone protection. We do not routinely prescribe HRT for patients with SLE and osteoporosis due to the uncertain risk of flare and the presence of alternative, effective antiresorptive agents.

### Cytotoxic Drugs

The onset of active lupus with major organ involvement is often rapid and requires prompt, aggressive therapy with cytotoxic agents, preferably by specialists to prevent potential disastrous sequelae. Moreover, the frequency with which this occurs in a given population base such as an average catchment area of 250 000 though not rare, is uncommon. Thus the nature of this condition is such that controlled trials are challenging to design and require an international collaborative effort to generate evidence guiding best practice. Placebo controlled trials, though deemed the “gold standard” clearly have no place in this setting. Thus up until the past decade or so many rheumatologists have largely relied on their own individual experience combined with data from small open labelled studies to guide therapy. This is now rapidly changing with greater national and international collaboration between centres.

The mainstay of treating active lupus with major organ involvement is broad spectrum immunosuppression with the ultimate aim of preventing irreversible organ damage. The drugs most frequently employed are azathioprine or cyclophosphamide together with corticosteroids, often in high doses. The kidney is the major organ most frequently threatened by active lupus. The group from the National Institute of Health at Bethesda have argued strongly that intravenous pulses of cyclophosphamide, monthly for six months and subsequently every three months for two years, is the treatment of choice in patients with severe renal involvement when compared with pulsed methylprednisolone alone. Some evidence supports the combination of pulsed methylprednisolone and cyclophosphamide as being superior to cyclophosphamide alone. The indiscriminate use of cyclophosphamide, however, is limited by its side effect profile (profound nausea, alopecia, infertility especially in patients over the age of 30, bone marrow suppression) and consequently has made others more wary about its routine use. In common with many European groups, we prefer to use oral prednisolone with azathioprine in mild to moderately active renal lupus reserving pulsed cyclophosphamide for severe renal involvement (fig 2). Moreover specific changes on the renal biopsy in histology/immunofluorescence as well as confirming the diagnosis can be used to score a validated activity and chronicity index. Thus a renal biopsy may guide the treating physician in stratifying the level of therapy required. However, before a renal biopsy may be safely

---

**Figure 2** Management of renal lupus based on our own current practice.
performed adequate control of blood pressure is mandatory. Such control is a key element in managing lupus nephritis effectively; whatever immunosuppressive regimen is chosen. A combination of antihypertensive agents is often required to prevent irreversible loss of renal function. The early recognition of lupus nephritis combined with appropriate, aggressive immunosuppressive therapy and attention to blood pressure control has meant that very few patients progress to end stage renal failure compared with 20–30 years ago. However there are occasional patients in whom, despite the above measures and good compliance, fail to gain adequate long term control and eventually require renal replacement therapy. Though it is relatively uncommon for a lupus patient with a transplanted kidney to develop lupus nephritis in the transplanted kidney,22 as reviewed by Stone et al lupus patients having received a renal transplant do not fare as well as those whose end stage renal disease has other causes.23

Azathioprine may also be used as a steroid sparing agent in patients whom reducing the dose of prednisolone, albeit slowly, results in a flare. For example, a patient who experiences pleuritic pain at a dose of prednisolone below 10 mg daily may remain symptom free on 5 mg and azathioprine 100 mg daily. The maximum dose of azathioprine we tend to escalate to is 2–3 mg/kg/day, though sufficient control may be gained with lower doses. There is some debate as to whether patients on azathioprine should be genotyped for thiopurine methyltransferase (TPMT). Azathioprine is metabolised to its active metabolite 6-mercaptopurine. This in turn undergoes intracellular conversion to thioguanine nucleotides that incorporate into DNA, producing an antiproliferative effect. Alternatively mercaptopurine is methylated to inactive metabolites by TPMT. TPMT exhibits genetic polymorphism with about 10% having intermediate activity and about one in 300 having TPMT deficiency.24 These patients are in danger of rapidly accumulating high levels of antiproliferative thioguanine nucleotides in haemopoietic tissues at usually therapeutic doses of azathioprine, hence rendering them at risk of severe marrow suppression. This has led some to advocate routine TPMT genotyping on patients starting azathioprine.25 However a study in SLE patients on azathioprine showed that drug related neutropenias occur despite normal TPMT activity.26 Furthermore TPMT activity cannot predict liver toxicity. Our practice is in line with the British Society of Rheumatology guidelines: (in adults) azathioprine is started at 50 mg a day and increased by 25 mg per week to an eventual maintenance dose of 50 mg/day. Weekly monitoring blood tests are performed for the first six weeks or until the dose is stable. Monitoring bloods are then done monthly thereafter. Whilst TPMT genotyping may augment azathioprine monitoring, we feel that the above monitoring measures are probably sufficient and do not feel that TPMT typing should replace regular blood monitoring.

Surprisingly, though methotrexate is the first line therapy for rheumatoid arthritis, its potential as a steroid sparing agent in SLE has been infrequently studied. A few studies to date have shown that methotrexate may have a place in the treatment of patients in whom cutaneous and articular manifestations have proved refractory to hydroxychloroquine27 and low dose prednisolone.28

Mycophenolate mofetil is a relatively new immunosuppressive agent now rapidly establishing a role in treating severe lupus nephritis refractory to other cytotoxic agents. Mycophenolate in combination with prednisolone has been compared to cyclophosphamide/prednisolone combination in the treatment of renal lupus.29 Both regimens were equally effective with fewer side effects in the mycophenolate group. Thus the use of this agent is likely to increase in the future and based on current evidence should certainly be considered if cyclophosphamide has failed.

OTHER “STANDARD” TREATMENTS

Plasma exchange

The concept of removing presumably pathogenic circulating immune complexes seems at first glance to offer a therapeutic advantage. Thus in the late 1970s and early 1980s there was a great vogue for using plasma exchange. After a short time, however, many disadvantages became apparent. As reviewed elsewhere limitations in its use include a “rebound” phenomenon within a few days/weeks, technical difficulties of requiring central venous access with associated complications, and patient discomfort.30 This is also an expensive form of therapy. Even in combination with pulsed cyclophosphamide no additional benefit over pulsed cyclophosphamide alone is seen.31

Dietary therapy

A frequently asked question in clinic is whether dietary modification may help. In the laboratory, altering the course of the disease may be achieved in a lupus mouse model (NZB/W and MRL-lpr/lpr mice). Caloric and in particular fat restriction is beneficial as is total zinc reduction. Moreover fish oil supplementation together with a low saturated fat diet has been shown to be beneficial. This has also been seen in humans where a small study showed the beneficial effects of fish oil supplementation over a six month period.32 Calorie restriction, however, has no place in the patient with severely active lupus with major organ damage as these patients tend to be acutely unwell and hence in a hypercatabolic state.

Intravenous high dose gammaglobulins

Intravenous immunoglobulin has an established role in lupus patients with severe thrombocytopenia or immune neutropenia. When this approach is unsuccessful in treating thrombocytopenia, splenectomy is beneficial in four or five out of six cases provided the problem has not been left to become chronic.33 Its role in treating non-haematological manifestations of lupus is less clear. A small open labelled study has shown comparable benefit to cyclophosphamide in treating lupus nephritis,34 though this needs to be confirmed in larger randomised controlled studies.

Cyclosporin/Neoral therapy

Following earlier discouraging results with cyclosporin at high doses,35 some recent evidence has demonstrated that cyclosporin in low doses of 2.5–5 mg/kg/day may provide reasonable disease control and offer the opportunity for reduction in steroid over long term follow up.36 However there is an impressive side effect profile, notably hypertrichosis which develops in the majority of patients, and given cyclosporin’s nephrotoxicity it is best avoid in patients with significant renal impairment.

MANAGEMENT IN SPECIAL SITUATIONS

Pregnancy

Given that most patients with SLE are women of childbearing potential the question of managing pregnancy is a significant issue for many. Approximately 25% of patients do not go to full term, well in excess of 10% expected in healthy women. Those patients with antiphospholipid syndrome are especially likely to have recurrent miscarriages. Those with antibodies to Ro and La have a small chance (1:20) of having a child with neonatal lupus syndrome. In contrast to patients with rheumatoid arthritis those with lupus do not invariably become less active during pregnancy, though whether there is a greater incidence of flares is controversial. Thus careful monitoring is mandatory and on occasion pre-eclamptic toxemia may be difficult to distinguish from a flare. We strongly recommend co-managing pregnant SLE patients with an interested obstetrician.

Clearly dilemmas arise in pregnant lupus patients regarding appropriate treatment to control active disease. NSAIDS, hydroxychloroquine, high dose corticosteroids, and cytotoxic
agents are all best avoided during pregnancy according to the *British National Formulary*. However one must weigh potential benefits against risk and discuss possible options with the patient. Some drugs carry a low risk of problems while others like cyclophosphamide should be avoided altogether. The challenging area of pregnancy in lupus is reviewed by Mok and Wong, like cyclophosphamide should be avoided altogether. The patient. Some drugs carry a low risk of problems while others benefits against risk and discuss possible options with the patient. Some drugs carry a low risk of problems while others.

Table 3 Effects of medication in pregnancy

<table>
<thead>
<tr>
<th>Drug</th>
<th>Known effects on fetus</th>
<th>Current advice</th>
</tr>
</thead>
<tbody>
<tr>
<td>High dose aspirin and NSAIDs</td>
<td>Possible adverse effects on uterine contraction and platelet function. Patent ductus arteriosus</td>
<td>Avoid if possible—particularly final few weeks of pregnancy</td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td>Withdrawal during pregnancy associated with flares</td>
<td>Chloroquine but not hydroxychloroquine associated with congenital abnormalities and so best avoided</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>High doses associated with premature rupture of membranes, intra uterine growth retardation and maternal complications such as gestational diabetes, hypertension and avascular necrosis. No reports of teratogenicity</td>
<td>If possible avoid fluorinated corticosteroids such as dexamethasone and betamethasone which easily cross the placenta</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>Teratogenicity reported in animals. Sporadic cases such as preaxial polydactyl reported in humans. Most studies show that generally well tolerated</td>
<td>Best avoided but may be considered if immunosuppression deemed necessary</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>Teratogenicity well established in humans</td>
<td>Avoid during pregnancy. Effective contraception required during and for at least 3 months after discontinuation of treatment (includes males)</td>
</tr>
<tr>
<td>Mycophenolate mofetil</td>
<td>Toxicity seen in animal studies</td>
<td>Avoid during pregnancy. Effective contraception required during and for 6 weeks after discontinuation of treatment</td>
</tr>
<tr>
<td>Cyclosporin A</td>
<td>Not an animal teratogen. Studies have confirmed relative safety in pregnancy. Long term effects uncertain</td>
<td>May be considered if immunosuppression deemed necessary</td>
</tr>
</tbody>
</table>

Secondary antiphospholipid syndrome

Approximately 10% of SLE patients also have antiphospholipid syndrome (though around 25%–35% have antiphospholipid antibodies). In some patients antiphospholipid syndrome may be the predominant clinical phenotype and we have, rarely, seen patients deemed to have primary antiphospholipid syndrome develop SLE over time. In the main, however, our experience is that SLE is diagnosed first. In patients with this type of overlap problems may arise. For example, if a patient develops hypertension with mild proteinuria a lower threshold for biopsy is required to differentiate multiple small thrombi from “lupus” glomerulonephritis. The former requiring anticoagulation and the latter immunosuppression. The difficulties are compounded by the fact that patients with antiphospholipid syndrome are often thrombocytopenic. In some both immunosuppressives and long term anticoagulation are required.

Drug induced lupus

There is an ever growing list of drugs reported to induce lupus or “lupus-like” disease. Thus far in excess of 50 drugs have been reported, some well known and associated with a relatively high risk such as procainamide, hydralazine or phenytoin, and others not so well known and associated with relatively low risk, such as atenolol, enalapril, or statins for example.

Drug induced lupus is associated with the presence of antihistone antibodies, reported in some studies to be present in up to 100% of patients. Patients may be taking the offending drug for months or years before developing drug induced lupus and this should not be confused with the short term toxic effects that often are suffered by patients who are treated with pharmaceuticals.

Treating physicians should always consider this potential diagnosis, particularly in patients with atypical presenting features and taking other medications. If suspected, we would advocate a relatively low threshold for requesting antihistone antibodies and performing a literature search. Serum may need to be sent to a dedicated laboratory to perform antihistone antibody quantification and this often needs to be discussed with one’s own immunology department.

The mainstay of treatment is discontinuation of the offending drug once the diagnosis is established. Improvement and permanent resolution of symptoms often occurs within days or weeks after discontinuation. Serological abnormalities often take months to resolve. Patients may need to be on corticosteroid therapy if there is major organ involvement. However the prolonged use of corticosteroids or cytotoxic agents is not indicated in drug induced lupus in view of its self limiting nature after discontinuing the offending drug.

Finally it is worth mentioning the striking association between the use of tumour necrosis factor-alpha blockade therapy and the emergence of dsDNA autoantibodies. This therapy is now used widely for the treatment of severe, refractory rheumatoid arthritis. Studies have shown that around 10% of patients develop anti-dsDNA antibodies, although only a very small minority of these patients go on to develop clinical evidence of SLE. Hence though the development of these antibodies in patients on tumour necrosis factor-alpha
blockade is not an indication in itself to discontinue therapy, patients must be kept under careful review.

**POTENTIAL NOVEL THERAPIES**

Rapid developments in biotechnology over the past decade has offered the opportunity to develop a greater understanding of the immunopathogenic dysregulation characterising lupus and develop targeted therapy to interfere with this dysregulation at various levels. Reagents near or at clinical trial phase include biologics developed to modulate or inhibit T cell activation, T and B cell collaboration, anti-dsDNA antibody deposition, production of anti-dsDNA antibody complexes, complement activation/deposition, and cytokine activation. In addition autologous stem cell transplantation has been attempted for very severe refractory lupus with remission induced in the majority of the small number of patients recruited. Some of the new therapies currently under study are summarised in table 4.

**CONCLUSION**

The prognosis of SLE has improved considerably over the past 30–40 years with appropriate use of corticosteroids and cytotoxic agents. Nevertheless the treatment of lupus continues to present considerable challenges. Many have mild disease, while others may present or rapidly develop aggressive disease with irreversible organ damage requiring prompt use of broad spectrum immunosuppressive therapy with their inherent difficulties. Indeed weighing the potential benefits of treating active disease against the risks of therapy induced side effects often represents the greatest dilemma for many and every intervention requires that the patient be fully informed of potential risks. The rapid developments in biotechnology have often represented the greatest dilemma for many and every therapy requires that the patient be fully informed of potential risks. The rapid developments in biotechnology have often represented the greatest dilemma for many and every therapy requires that the patient be fully informed of potential risks. The rapid developments in biotechnology have thus been a cause of death in patients with SLE is increasingly recognised and presents further challenges for the future.

---

**Authors’ affiliations**

Y Ioannou, D A Isenberg, Centre for Rheumatology, Department of Medicine, University College London, London, UK

**REFERENCES**


---

**Table 4** Potential new targeted therapies for SLE

<table>
<thead>
<tr>
<th>Drug</th>
<th>Target</th>
<th>Rationale</th>
<th>Trial data available</th>
</tr>
</thead>
<tbody>
<tr>
<td>LUP 394</td>
<td>B cells</td>
<td>Inhibit production of anti-dsDNA antibodies. Cross links anti-dsDNA antibodies leading to anergy and deletion of B cells rather than activation, as drug does not carry T cell epitope and cannot recruit T cell help.</td>
<td>To date no evidence of reduced rate of renal flare. Phase II clinical studies to identify precise potential role continue.</td>
</tr>
<tr>
<td>Anti-CD20 antibody</td>
<td>B cells</td>
<td>Inhibits production of anti-dsDNA antibodies. CD20 expressed on all activated B cells and when recognised by anti-CD20 antibody causes lysis of these cells. Currently licensed for non-Hodgkin’s lymphoma.</td>
<td>Recent small study has demonstrated safety and some efficacy at higher doses. Currently underway at our centre is an open labelled study. Thus far 7 patients treated with encouraging results. Data from larger controlled studies required.</td>
</tr>
<tr>
<td>Anti-IL-10 antibodies</td>
<td>IL-10</td>
<td>IL-10 consistently raised in SLE.</td>
<td>Small study of 6 patients treated showing improvement in skin and joint manifestations.</td>
</tr>
<tr>
<td>Anti-CD40 ligand (L)</td>
<td>CD40 L</td>
<td>C40L expressed on T cells provides an important co-stimulus to T cell activation. This interaction also has significant effects on B cells, for example, augmenting B cell response to cytokines and causing antibody isotype switching.</td>
<td>One study found this to be tolerated well. However a recent study was discontinued due to concerns regarding major vascular events, namely myocardial infarction and stroke.</td>
</tr>
<tr>
<td>Leflunomide</td>
<td>T and B cells</td>
<td>Inhibits pyrimidine synthesis thus blocking RNA and DNA synthesis in T and B cells and hence inhibits proliferation of these cells. Currently licensed for rheumatoid arthritis.</td>
<td>First short term studies have shown it to be safe and reasonably effective.</td>
</tr>
</tbody>
</table>

IL, interleukin.


Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge
Y Ioannou and D A Isenberg

Postgrad Med J 2002 78: 599-606
doi: 10.1136/pmj.78.924.599

Updated information and services can be found at:
http://pmj.bmj.com/content/78/924/599

These include:

References
This article cites 36 articles, 2 of which you can access for free at:
http://pmj.bmj.com/content/78/924/599#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Connective tissue disease (51)
- Immunology (including allergy) (394)
- Systemic lupus erythematosus (12)
- Drugs: musculoskeletal and joint diseases (59)
- Chemotherapy (37)
- Diet (61)
- Drugs: infectious diseases (221)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/